Daniel Erlanson

基本信息

浏览量：65

职业迁徙

个人简介

Dan is an inventor on more than fifteen issued US patents, an author of more than 40 scientific publications, and co-editor of two books on fragment-based drug discovery (FBDD).

研究兴趣

论文共 99 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Fragment-to-Lead Medicinal Chemistry Publications in 2022

Andrew J Woodhead,Daniel A Erlanson,Iwan J P de Esch,Rhian S Holvey,Wolfgang Jahnke,Puja Pathuri

Journal of medicinal chemistryno. 4 (2024): 2287-2304

引用0浏览0WOS引用

Discovery of FMC-376 a Novel Orally Bioavailable Inhibitor of Activated KRASG12C

Snahel Patel,Barun Bhhatarai,Philamer Calses,Daniel Erlanson,Robert Everley,Susan Fong, Phil Gerken,Johannes C. Hermann,Tiep Le, Li-kai Liu, Evan McMahon,Richard M. Neve,Tony Phan,Allison Roberts,Mikayla Shanafelt, Sophie Siemsgluess,Jocelyn Staunton,Yan Wang,Weiru Wang,Monika Williams,Kevin R. Webster

CANCER RESEARCHno. 7 (2023)

引用0浏览0引用

Abstract 5333: Combining Chemoproteomics with Machine Learning Identifies Functionally Active Covalent Fragments for Hard-to-drug Cancer Drivers

Johannes C. Hermann,Robert Everley,Laura Marholz,Matthew Berberich,Tzu-Yi Yang, Yu-Hsin Chao, Abduselam K. Awol,Michael Shaghafi, Han Yoon,Rohan Varma,Reed Stein,Karsten Krug,Emily Lachtara,Daniel Erlanson, Chris Varma,Kevin R. Webster

CANCER RESEARCHno. 7 (2023)

引用0浏览0引用

Fragment-to-Lead Medicinal Chemistry Publications in 2021

Louise Walsh,Daniel A. Erlanson,Iwan J. P. de Esch,Wolfgang Jahnke,Andrew Woodhead, Ella Wren

Journal of medicinal chemistry（2023）

引用13浏览0WOS引用

Therapeutics and Diagnostics Discovery

Daria Mochly‐Rosen,Kevin Grimes, Rami N. Hannoush, B Koch,Daniel A. Erlanson,Julie Saiki,Jennifer Wilson,Shelley Force Aldred,Adriana A. Garcia,Jin Billy Li,Rosa Bacchetta,Maria Grazia Roncarolo,Alma-Martina Cepika, Harry B. Greenberg,Steven N. Goodman,Michael A. Kohn

Springer eBookspp.33-100, (2023)

引用0浏览0引用

Introduction to the Themed Collection on Fragment-Based Drug Discovery

David C. Rees,Anna K. H. Hirsch,Daniel A. Erlanson

RSC medicinal chemistryno. 12 (2022): 1439-1439

引用1浏览0引用

Fragment-to-Lead Medicinal Chemistry Publications in 2020

Iwan J. P. de Esch,Daniel A. Erlanson,Wolfgang Jahnke,Christopher N. Johnson,Louise Walsh

Journal of medicinal chemistry（2022）

引用50浏览0WOS引用

Discovery of novel dual-acting KRAS^G12C inhibitors that target both the active and inactive forms of the protein

Philamer Calses,Sam Clark, Jacob Corpuz,Susan Fong, Phil Gerkin,Mohammad Hekmatnejad, Evan McMahon,Megan Murray,Truc Nguyen,Tony Phan,Allison Roberts,Phillip Schwartz,Mikayla Shanafelt,Hiroko Tanaka, Jennifer Tomczyk, John Widen,Monika Williams,John Eksterowicz,Daniel Erlanson,Marie Evangelista,Johannes Hermann,Richard M. Neve,Snahel Patel,Kevin R. Webster

Cancer Researchno. 12 (2022): 3601-3601

引用0浏览0引用

The future of covalent inhibition

Gyorgy M. Keseru,Daniel A. Erlanson

Annual Reports in Medicinal Chemistry（2021）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn

Senior Vice President

论文共 99 篇作者统计合作学者相似作者